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Breast cancer is the most common malignancy in South African (SA) 
women, accounting for ~22% of local cancer cases,[1] and 5 - 10% of 
these cases are considered to be hereditary.[2] Historically, hereditary 
breast cancer (HBC) was associated primarily with pathogenic 
variants in the BRCA1 and BRCA2 genes, but in the post-genomic 
era there is increasing evidence of the contributions of other genes 
to inherited breast cancer risk.[3,4] This means that clinicians and 
genetic counsellors are faced with an ever-broadening menu of 
genetic testing options for patients. Our colleagues have published 
on strategies for patients in the public healthcare sector,[5-7] but no 
data are available on the detection rates of the various testing options 
available to SA patients in the private sector. Information regarding 
the detection rates of these tests may assist managing healthcare 
providers to select the most appropriate and economical approach to 
genetic testing for individuals and families with HBC.
Indications for genetic testing
Various international groups have proposed guidelines and criteria 
for identifying candidates for genetic testing.[8-10] However, other 
groups have raised concerns about these criteria being too stringent, 
resulting in more than half of patients harbouring disease-causing 
variants being missed.[11] In line with these findings, the American 
Society of Breast Surgeons recommends that genetic testing be made 
available to all patients with a personal history of breast cancer,[12] 
although this approach in patients diagnosed at >65 years without 
a significant family history of relevant cancers has a very low 
probability (<2%) of yielding results with clinical utility.[3,8]
Currently no national SA consensus guidelines exist for genetic 
testing for persons at risk of HBC. Individual academic units and 
genetic practitioners have adapted international guidelines[8-10] to our 
local context, taking into consideration founder effects among certain 
population groups and the availability of tests in different healthcare 
sectors.[5-7]
It is internationally recognised and recommended that any genetic 
testing be performed in the context of appropriate genetic counselling. 
This process aims to ensure informed consent by providing the 
patient with information regarding testing, including the benefits, 
risks and limitations of different testing options. The potential 
complexities of results, including the chance of identifying variants of 
uncertain clinical significance (VUSs), and the implications of results 
for the family are also discussed.[3,7,8]
Overview of current genetic testing 
strategies in the private sector
Founder screening
In the local context, founder variant testing may be requested as a 
first-line genetic test for individuals of Ashkenazi Jewish or Afrikaner 
ancestry.[5-7,13] It is important to note that there are >2 000 and >3 000 
known ‘likely pathogenic’ and ‘pathogenic’ variants in the BRCA1 
and BRCA2 genes, respectively (as listed in ClinVar), and each 
founder screen tests for only three of these variants (Table 1). It is 
therefore not appropriate to utilise these tests as first-line screening 
for individuals who are not of known Afrikaner or Jewish ancestry. 
Additionally, individuals who have negative results from these limited 
founder screens should be offered more extensive testing options, 
such as full sequencing of the BRCA1 and BRCA2 genes.
BRCA1 and BRCA2 full gene sequencing
For patients who are not of known Afrikaner or Ashkenazi Jewish 
ancestry, clinicians may request comprehensive screening of the full 
BRCA1 and BRCA2 genes, or utilise multigene panels that include 
additional high- or moderate-risk genes such as PALB2, CHEK2 and 
ATM. Germline disease-causing variants in BRCA1 and BRCA2 are 
estimated to account for ~24% of families with inherited breast and/or 
ovarian cancer in European populations.[8] Comprehensive screening 
of the full coding regions of genes is usually achieved via a next-
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generation sequencing (NGS) approach. It is important to select an 
approach that includes deletion/duplication analysis (either through 
NGS analysis or complementary methods such as multiplex ligation-
dependent probe amplification (MLPA)) since ~10% of pathogenic 
variants in BRCA1 and BRCA2 can only be detected in this manner.[14] 
Although the cost of NGS-based testing has decreased substantially in 
the past decade, local NGS-based testing still comes with a significant 
cost and turnaround times of more than 6 weeks (Table 1).
Multigene panels
More recently, research has shown that more than half of the disease-
causing variants underlying HBC can be found in genes other than 
BRCA1 and BRCA2.[15] These non-BRCA genes include ATM, CHEK2 
and PALB2, among others, and are also tested using an NGS-based 
approach. Multigene panel tests including these genes are available 
locally, although many clinicians and genetic counsellors opt to refer 
to the international laboratory Invitae (USA) because of the lower 
costs, quicker turnaround time, and additional benefits such as 
testing of family members at no additional cost if a clinically relevant 
variant is identified (Table 1). No data are available on the uptake of 
local multigene panel tests.
The laboratory where the study was conducted does not offer 
in-house multigene panel testing for HBC, but sends these requests to 
Invitae laboratory. Multigene panels offered by other local laboratories 
are not included in this article.
When referring for multigene panel testing, it is important to 
consider the likelihood of detecting VUSs. This risk increases the 
more genes the panel selected contains. Rather than falling into 
pathogenic or benign categories, these are sequence variants for 
which the association with disease risk is unclear based on currently 
available evidence. Laboratories routinely report on VUS results to 
allow for periodic review and potential reclassification based on new 
evidence. However, until a VUS is reclassified, these variants should 
not be used in clinical decision-making.[16]
Medical aid scheme considerations
The selection of tests in the private sector is often influenced by cost 
and medical aid scheme reimbursement. Medical aid schemes do 
not currently cover tests sent to international referral laboratories. 
Patients may apply to their medical scheme for reimbursement 
of local genetic testing, but this is often subject to internal risk 
assessment criteria, which differs per scheme. In our experience, 
the full cost of local BRCA1 and BRCA2 sequencing has rarely been 
covered by medical schemes, and patients often had out-of-pocket 
expenses of a significant proportion. In recent months it has become 
evident that more medical schemes are reimbursing these local 
tests in full; this option may therefore become more attractive to 
patients and healthcare providers. It is advisable for patients and 
their healthcare team to discuss the economic impact of all testing 
options, both local and international, and apply to medical schemes 
for approval prior to any testing.
Methods
An internal database was reviewed to determine the results obtained 
from HBC patient referrals to our laboratory over a period of 3 years 
(2016 - 2018). This period was selected since it represented the most 
comprehensive data set for the various testing options. All referrals 
were included in the data set, except for referrals for family variant 
Table 1. Summary of genetic testing options
Afrikaner founder screen Ashkenazi Jewish founder screen BRCA1/2 sequencing (local) Multigene panel (international)
Details 3 variants
• BRCA1 c.1374delC 
(p.Asp458Glufs)
• BRCA1 c.2641G>T 
(p.Glu881Ter)
• BRCA2 c.7934delG 
(p.Arg2645Asnfs)
• 3 variants
• BRCA1 c.68_69delAG 
(p.Glu23Valfs)
• BRCA1 c.5266dupC 
(p.Gln1756Profs)
• BRCA2 c.5946delT 
(p.Ser1982Argfs)
Sequencing of BRCA1 
and BRCA2 genes (>5 000 
variants)
Sequencing of multiple genes, 
including BRCA1, BRCA2, 
CHEK2, ATM
Cost* ~ZAR2 200 ~ZAR2 200 ~ZAR13 500 (varies 
between laboratories)
~ZAR4 600
(USD250 + ZAR750 courier/
handling fee)
Turnaround time 1 - 2 weeks 1 - 2 weeks 6 - 8 weeks 2 - 3 weeks 
(1 week for STAT Panel†)
Disadvantages Only 3 variants tested
Not appropriate for 
individuals of other 
ancestries
Only 3 variants tested
Not appropriate for individuals 
of other ancestries
Risk of missing 40 - 50% of 
pathogenic variants in other 
HBC-associated genes
Long turnaround times
Patient may need to pay a 
significant proportion of 
cost
High VUS rates
Rarely covered by medical aid
Advantages Cost-effective first-line 
test for individuals with 
Afrikaner ancestry
May be covered (in full 
or partially) by medical 
aid scheme
Cost-effective first-line test for 
individuals with Ashkenazi 
Jewish ancestry
May be covered (in full or 
partially) by medical aid scheme
Higher detection rates than 
founder screens
May be covered (in full or 




Free testing available for 
family members
HBC = hereditary breast cancer; VUS = variant of uncertain significance.
*Approximate costs (private rates) correct as at March 2020.
†BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53, ATM and CHEK2.
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testing (testing of at-risk individuals in a family where a known 
pathogenic variant has been detected) which were excluded. Referrals 
came from private clinicians ranging from general practitioners 
to specialist physicians and genetic specialists throughout SA. The 
results from founder screens (n=704), in-house BRCA1/2 sequencing 
(n=260) and internal multigene panel send-aways (n=723) were 
de-identified and reviewed to determine the positive and negative 
pick-up rates for each test. The VUS rate was also calculated 
for multigene panel tests. Clinical and demographic information 
rarely accompanies these referrals. It was therefore not possible to 
determine how appropriate requests were, based on the patients’ 
ancestral backgrounds.
Ethics approval
Ethics approval was granted by the University of the Free State 




Based on 655 requests for Afrikaner variant testing, 15% of results 
were positive for one of the three variants tested (Fig. 1). This is 
significantly lower than the detection rates which can be achieved 
in well-defined Afrikaner cohorts.[5,6] The most commonly detected 
variant was BRCA2 c.7934del (p.Arg2645Asnfs, historically referred 
to as BRCA2 8162delG) which was detected in 11% of referrals. This 
is in line with variant distributions reported in other local studies.[5,6]
Fewer requests were received for Ashkenazi Jewish founder variant 
screening (n=49). Eight percent of these requests were positive 
for either the BRCA1 c.5266dupC (p.Gln1756Profs) or BRCA2 
c.5946delT (p.Ser1982Argfs) variants (Fig. 1). No individuals were 
positive for the BRCA1 c.68_69delAG (p.Glu23Valfs) variant.
Sequencing of the BRCA1 and BRCA2 genes
Based on 260 referrals for BRCA1 and BRCA2 NGS-based sequencing 
over a 3-year period, we noted a 7% pathogenic variant pick-up rate. 
Sixty-five percent of disease-causing variants were found in BRCA1 
(Fig. 2), which is in line with internationally published distributions 
of BRCA1 v. BRCA2 disease-causing variants (66% v. 34%).[14]
Multigene panels
From a dataset of >700 referrals to Invitae for multigene panel testing, 
we noted a positive pick-up rate ranging between 17% and 21%, 
depending on the panel selected. The 9-gene Breast Cancer STAT 
Panel (consisting of BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, 
TP53, ATM and CHEK2) showed the highest pick-up rate of 21% 
(Fig. 3). The 20-gene Breast and Gyn Cancers Guidelines-Based Panel 
and the 47-gene Common Hereditary Cancers Panel showed positive 
pick-up rates of 17% and 19%, respectively. We acknowledge that 
referrals for the STAT Panel may be biased towards affected patients 
in terms of needing an urgent result for clinical decision-making, 
compared with other panels that may include unaffected patients 
where no affected family member is available to test.
The risk of a higher VUS rate when larger panels are used is 
demonstrated in Fig. 3, with the largest 47-gene panel having a VUS 
pick-up rate of 56%. When a VUS is reported, the result is neither 
actionable nor completely reassuring; the interpretation is therefore 
complex and should take the family history as well as other clinical 
factors into account. The higher the VUS rate, the more difficult 
the result becomes to interpret, and these results become more 
challenging to convey and explain to the patient.[3]
Multigenes and multidisciplinary teams
As mentioned previously, it is now possible to test for genetic 
contributions to HBC other than BRCA1 and BRCA2. Based on our 
referrals for multigene panel testing, close to 40% of disease-causing 
variants were found in genes other than BRCA1 or BRCA2 (Fig. 4). 
This highlights the importance of comprehensive genetic testing, 
since the clinical management and associated risks of breast, ovarian 
and other cancers (such as colon, gastric or prostate cancer) vary 
greatly, depending on the causative gene.[8] Larger panels could also 
include genes that are relatively newly identified, with the implication 
1493delC       8162delG            E881X                   Negative
Afrikaner founder variant results
5382insC             6174delT              Negative
Jewish founder variant results












 Negative              BRCA1                   BRCA2
Fig. 2. Results of in-house BRCA1 and BRCA2 next-generation sequencing-
based screening.
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that cancer risks are not well delineated and 
no guidelines exist for medical management 
or the value of family predictive testing.[3] 
Caution should be exercised when selecting 
a panel in which these genes are included.
Discussion
This retrospective study is the first to 
evaluate and compare the results obtained 
from different genetic testing options for 
HBC in the SA private sector. A summary 
of these testing options is given in Table 1. 
A summary of the test details and positive 
pick-up rates is provided in Table 2.
The results of this study are in line 
with findings from other international 
publications in terms of positive pick-up 
rates for the multigene panels and VUS 
rates that increase with the larger multigene 
panels.[17,18]
Our data set has shown positive pick-
up rates of 15% and 8% for the Afrikaner 
and Jewish founder screens. Previous 
studies have indicated that these rates can 
be significantly higher in well-defined 
and appropriate patient populations.[5,6,19] 
There is a concern that these tests are being 
requested inappropriately, and are often 
selected because of lower cost, quicker 
turnaround times and medical aid scheme 
reimbursement, rather than being based on 
clinical utility and family history/ancestry. 
The benefit of medical scheme coverage and 
lower cost will have to be weighed against 
the need for further testing if results are 
negative. The multigene panels will pick up 
these six founder variants, in addition to 
other variants in BRCA1 and BRCA2 and 
the other HBC-associated genes in the panel 
selected.
Our data suggest that in the private sector 
in SA, targeted multigene panels (such 
as the Invitae Breast Cancer STAT or the 
Invitae Hereditary Breast and Gyn Cancers 
Guidelines-Based Panel in this data set) 
are appropriate testing options for patients 
with suspected HBC. While positive pick-
up rates are high (17 - 21%), the VUS rate 
is lower than with larger panels such as the 
Invitae Common Hereditary Cancer Panel 
(20% v. 56%), making result interpretation 
less complex. While the pick-up rate for 
multigene panels is much higher than with 
BRCA1 and BRCA2 sequencing alone (17 - 
21% v. 7%), the cost is also lower with the 
international multigene panels than local 
full gene sequencing of BRCA1 and BRCA2 
(Table 1). Therefore, considering both cost 
and pick-up rate, the international send-away 
multigene panels may be a more suitable 
option for patients than local BRCA1 and 
BRCA2 sequencing. However, it is essential 
that patients and healthcare providers engage 
with medical schemes prior to any genetic 
testing, since schemes are covering local 
NGS-based testing more frequently.
We have alluded to some of the com-
plexities involved in choosing the most 
appropriate genetic testing approach for 
breast/ovarian cancer patients, as well 
as the intricacies that may arise with the 
interpretation of genetic testing results. 
For these reasons it is recommended that 
multigene testing is ideally offered in the 
context of professional genetic expertise for 
pre- and post-test genetic counselling. [3,8] 
Genetic counselling services are still under-
utilised throughout SA and only available 
in some of the larger centres,[20] although 
the majority of genetic counsellors in 
private practice offer telephonic or video-
call consultations. Patients may also be 
referred to genetic services within the major 
academic hospitals.
Conclusions
In the SA private sector, multigene panel tests 
for HBC have good clinical utility in terms of 
pick-up rate for pathogenic variants. Founder 
mutation screens should only be requested 
in very specific contexts. Decisions regarding 
test options and interpretation of results 
can be complex and genetic counselling by 
genetic specialists is advised. 
While national capacity building is 
important in order to expand the scope of 
local genetic services, the significantly lower 
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Fig. 3. Results of referrals to Invitae for multigene panel testing. (STAT Panel = BRCA1, BRCA2, 
CDH1, PALB2, PTEN, STK11, TP53, ATM and CHEK2; VUS = variant of uncertain significance.)
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Fig. 4. Multigene panel results.
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make this option an attractive alternative. Further discussion is 
needed among product distributors, testing laboratories, healthcare 
providers, medical schemes, patients and their families, in order to 
increase the availability and accessibility of necessary genetic testing 
services in SA.
Study limitations
This study was conducted at a single laboratory in private practice 
in SA and results are therefore biased towards a population group 
having access to private medical schemes or an income level that 
would support self-payment for tests. Only data and testing options 
available for this laboratory were included in the article.
A correlation was not made between the pick-up rate of tests and 
the patient clinical information, as these data were not available.
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15% 8% 7% 17 - 21%
